InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.815 0.005 (0.62%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$389 Trading Halt 14 Nov 2011 9:27AM $1.075 $0.815 fallen by 24.19%
$389 Appendix 4C - quarterly 27 Oct 2011 11:44AM $1.120 $0.815 fallen by 27.23%
$389 Starpharma secures FDA agreement on BV treatment Phase 3 10 Oct 2011 9:26AM $0.990 $0.815 fallen by 17.68%
$389 Annual report and full year financial results 29 Aug 2011 1:56PM $1.215 $0.815 fallen by 32.92%
$389 GSK awarded funds for dermal treatment with SPL`s dendrimers 22 Aug 2011 9:31AM $1.025 $0.815 fallen by 20.49%
$389 SPL terminates Reckitt agreement and signs with Ansell 17 Aug 2011 5:24PM $1.150 $0.815 fallen by 29.13%
$389 SPL Commences VivaGel Bacterial Vaginosis Prevention Study 15 Aug 2011 8:50AM $1.380 $0.815 fallen by 40.94%
$389 Appendix 4C - quarterly 28 Jul 2011 2:22PM $1.540 $0.815 fallen by 47.08%
$389 Starpharma advances agrochemical program 12 Jul 2011 11:31AM $1.660 $0.815 fallen by 50.90%
$389 Advances leading cancer therapeutic in drug delivery program 29 Jun 2011 11:33AM $1.425 $0.815 fallen by 42.81%
$389 VivaGel Demonstrates Efficacy in Bacterial Vaginosis 23 May 2011 10:02AM $1.490 $0.815 fallen by 45.30%
$389 VivaGel Coated Condom Licence Agreement with Okamoto Japan 10 May 2011 11:30AM $1.415 $0.815 fallen by 42.40%
$389 Appendix 4C - quarterly 27 Apr 2011 1:13PM n/a $0.815 n/a
$389 Completes enrolment for Phase 2 study of VivaGel for BV 23 Mar 2011 11:46AM $1.030 $0.815 fallen by 20.87%
$389 SPL to expand agricultural program through $250,000 funding 3 Mar 2011 9:25AM $1.130 $0.815 fallen by 27.88%
$389 Half Yearly Report and Accounts 21 Feb 2011 2:11PM $1.030 $0.815 fallen by 20.87%
$389 Response to ASX Query 9 Feb 2011 1:52PM $1.000 $0.815 fallen by 18.50%
$389 Appendix 4C - quarterly 31 Jan 2011 10:38AM $1.360 $0.815 fallen by 40.07%
$389 Response to an ASX Price Query 18 Nov 2010 9:37AM $0.780 $0.815 risen by 4.49%
$389 Starpharma`s partner SSL acquired by Reckitt Benckiser 4 Nov 2010 9:24AM $0.690 $0.815 risen by 18.12%
$389 Appendix 4C - quarterly 25 Oct 2010 1:36PM $0.690 $0.815 risen by 18.12%
$389 Starpharma Expands Lilly Partnership 30 Sep 2010 9:25AM $0.560 $0.815 risen by 45.54%
$389 Annual Report and full year financial results 25 Aug 2010 4:00PM $0.500 $0.815 risen by 63%
$389 VivaGel condom patent grant extends coverage 18 Aug 2010 10:39AM $0.520 $0.815 risen by 56.73%
$389 Starpharma announces Phase 2 BV study of VivaGel 16 Aug 2010 10:49AM $0.520 $0.815 risen by 56.73%

751 - 775 of 894 results

Page 31 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.